Medistep Healthcare Limited is a dynamic and innovative pharmaceutical company that has carved a strong niche in the healthcare industry. The company specializes in manufacturing sanitary pads, energy powder, and trading a diverse range of pharmaceutical products. With a firm commitment to improving well-being globally, Medistep Healthcare has emerged as a trusted brand known for delivering high-quality products and exceptional customer service.

The company’s IPO is a Fixed Price Issue amounting to ₹16.09 Crores, consisting entirely of a fresh issue of 37.44 lakh shares priced at ₹43 per equity share. The subscription window opens on August 8, 2025, and closes on August 12, 2025. The allotment is expected to be finalized on or about August 13, 2025, with shares tentatively scheduled to be listed on the NSE SME on or about August 18, 2025.

At the IPO price of ₹43 per share, Medistep Healthcare's market capitalization will be approximately ₹61.10 Crores. The IPO lot size is 3,000 shares, and individual investors must apply for a minimum of 2 lots (6,000 shares), amounting to an investment of ₹2,58,000.

The IPO is managed by Fast Track Finsec Private Limited as the book running lead manager, Cameo Corporate Services Limited as the registrar, and Nirman Share Brokers Private Limited as the market maker.

The company’s Grey Market Premium (GMP) currently stands at ₹4, indicating expected listing gains of around 9.30%. However, GMP depends on unregulated demand and supply dynamics and should be considered only for informational purposes.

Financially, Medistep Healthcare has shown steady growth over the years. Revenues from operations for FY25, FY24, and FY23 were ₹4,965.85 Lakh, ₹3,162.52 Lakh, and ₹2,773.69 Lakh, respectively. EBITDA rose from ₹142.91 Lakh in FY23 to ₹560.11 Lakh in FY25, while profit after tax increased from ₹92.10 Lakh to ₹414.42 Lakh during the same period. These numbers indicate consistent improvement in profitability and operational efficiency.

Key financial ratios reveal a pre-issue EPS of ₹4.01 and a post-issue EPS of ₹2.92 for FY24. The pre-issue Price to Earnings (P/E) ratio is 10.72x, and post-issue P/E stands at 14.74x, which is reasonable compared to the industry average P/E of 69x, indicating that the IPO is fairly priced. The company’s Return on Capital Employed (ROCE) is 38.91%, and Return on Equity (ROE) is 29.06%, underscoring strong capital efficiency and investor returns.

The IPO proceeds will be used for purchasing new plant and machinery for expansion, meeting working capital requirements, corporate expenses, and issue-related costs.

Led by promoters Mr. Girdhari Lal Prajapat, Mr. Dabhi Vipul Gobarbhai, and Ms. Prajapati Hetalben Girdharilal, all veterans of the Indian pharmaceutical industry, Medistep Healthcare is focused on sustainable growth and innovation. Their combined experience and forward-looking management strategies have helped the company build a robust foundation in the competitive pharmaceutical sector.

Given the solid financial performance, promising market position, and attractive valuation, risky investors looking for potential listing gains may consider applying to Medistep Healthcare Limited IPO. However, as with all investments, it is recommended to evaluate risks carefully and consult financial advisors before making any investment decisions.

The Upcoming IPOs in this week and coming weeks are Studio LSD, Shreeji Shipping Global, Patel Retail.

The Current active IPO are Regaal Resources, Mahendra Realtors and Infrastructure, Bluestone Jewellery and Lifestyle, Icodex Publishing Solutions, Star Imaging and Path Lab, Medistep Healthcare, ANB Metal Cast.

Start your Stock Market Journey and Apply in IPO by Opening Free Demat Account in Choice Broking FinX.

Join our Trading with CA Abhay Telegram Channel for regular Stock Market Trading and Investment Calls by CA Abhay Varn - SEBI Registered Research Analyst.